- Question from Marcello: Doctors, overall did you take away a general sense of positive news and advances from this ASCO meeting, whether the changes and improvements were big or small?
- Answers - Carol Kaplan Absolutely. We are excitingly moving into an era of treating patients in a more targeted manner. Breast cancer research is moving away from treating a broad range of breast cancer patients with general anti-cancer drugs and moving towards the art of picking an individualized therapy for each subset of breast cancer, whether it be ER or PR positive or HER2 positive or associated with the BRCA mutations. Each year at ASCO, we find we're hearing yet another way to allow women to be survivors after breast cancer.
- Generosa Grana, M.D., F.A.C.P I would absolutely agree with that. It is an incredibly exciting time to be taking care of women with breast cancer. Metastatic disease is being approached more as a chronic disease and many of the exciting findings from advanced cancer are being moved to the early-stage setting where they are likely to have a greater impact on survival. The future holds tremendous promise for breast cancer patients.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.